Loading…
An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers
Adverse drug reactions (ADRs) are a major cause of hospital admissions, prolonged hospital stays, morbidity, and drug-related mortality. In this study, we sought to identify the most frequently reported medications and associated side effects in adolescent-aged patients in an effort to prioritize cl...
Saved in:
Published in: | F1000 research 2018, Vol.7, p.677-677 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5462-2394eb6d5e5586ada6f2c7a0de4b751d7ba3ae77e7f18b3cd5dfe662b0295e5e3 |
---|---|
cites | cdi_FETCH-LOGICAL-c5462-2394eb6d5e5586ada6f2c7a0de4b751d7ba3ae77e7f18b3cd5dfe662b0295e5e3 |
container_end_page | 677 |
container_issue | |
container_start_page | 677 |
container_title | F1000 research |
container_volume | 7 |
creator | Eugene, Andy R Eugene, Beata |
description | Adverse drug reactions (ADRs) are a major cause of hospital admissions, prolonged hospital stays, morbidity, and drug-related mortality. In this study, we sought to identify the most frequently reported medications and associated side effects in adolescent-aged patients in an effort to prioritize clinical pharmacology consultation efforts for hospitals seeking to improve patient safety.
Quarterly reported data were obtained from the United States Food and Drug Administration Adverse Events Reporting System (FAERS) from the third quarter of 2014 and ending in the third quarter of 2017. We then used the GeneCards database to map the pharmacogenomic biomarkers associated with the most reported FAERS drugs. Data homogenization and statistics analysis were all conducted in R for statistical programming.
We identified risperidone (10.64%) as the compound with the most reported ADRs from all reported cases. Males represented 90.1% of reported risperidone cases with gynecomastia being the most reported ADR. Ibuprofen OR=188 (95% CI, 105.00 - 335.00) and quetiapine fumarate OR=116 (95% CI, 48.40 - 278.00) were associated with the highest odds of completed suicide in teenagers. Ondansetron hydrochloride OR=7.12 (95% CI, 1.59 - 31.9) resulted in the highest odds of pneumothorax. Lastly, olanzapine (8.96%) represented the compound with the most reported drug-drug interactions cases, while valproic acid OR=221 (95% CI, 93.900 - 522.00) was associated with the highest odds of drug-drug interactions.
Despite any data limitations, physicians prescribing risperidone in males should be aware of the high rates of adverse drug events and an alternative psychotropic should be considered in male patients. Further, patients with a history of pneumothorax or genetically predisposed to pneumothorax should be considered for an alternative antiemetic to ondansetron hydrochloride, due to increased odds associated with the drug and adverse event. |
doi_str_mv | 10.12688/f1000research.14970.2 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d697c38aebdf4bac8463a5932d5c07d9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d697c38aebdf4bac8463a5932d5c07d9</doaj_id><sourcerecordid>2115275100</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5462-2394eb6d5e5586ada6f2c7a0de4b751d7ba3ae77e7f18b3cd5dfe662b0295e5e3</originalsourceid><addsrcrecordid>eNpdkt1q3DAQhU1paUKaVwiC3vRmt_qxJbsXhSX0JxDoTXstxtLYq8UruZK8sM_Sl63YTUO2VxKacz5mRqeq7hhdMy7b9uPAKKURE0I02zWrO0XX_FV1zWktV6ym_PWL-1V1m9KuGGjXCcnV2-pKUK5Y07Lr6s_GkzDPIebFu3wkQ4jETM47AxOZtxD3YMIUxiPJEZxHWx6PyRkHPpEciNvPMRyQzJAd-kxsXEaSYMB8_EQ2JGKOIc1osisi8DAVcyJhIGAPGBOeDRGhKEJBOk8yooexFN9VbwaYEt4-nTfVr69fft5_Xz3--PZwv3lcmaaWfMVFV2MvbYNN00qwIAduFFCLda8aZlUPAlApVANre2FsYweUkveUd8WD4qZ6OHNtgJ2eo9tDPOoATp8eQhw1xOzMhNrKThnRAvZ2qHswbS0FNJ3gtjFU2a6wPp9Z89Lv0ZqykwjTBfSy4t1Wj-GgJatFJ0QBfHgCxPB7wZT13iWD0wQew5I0Z6zhZSxKi_T9f9JdWGLZ8UlVOhOKsaKSZ5UpP5EiDs_NMKpPcdIXcdKnOGlejHcvR3m2_QuP-At-BM4N</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2114633711</pqid></control><display><type>article</type><title>An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Eugene, Andy R ; Eugene, Beata</creator><creatorcontrib>Eugene, Andy R ; Eugene, Beata</creatorcontrib><description>Adverse drug reactions (ADRs) are a major cause of hospital admissions, prolonged hospital stays, morbidity, and drug-related mortality. In this study, we sought to identify the most frequently reported medications and associated side effects in adolescent-aged patients in an effort to prioritize clinical pharmacology consultation efforts for hospitals seeking to improve patient safety.
Quarterly reported data were obtained from the United States Food and Drug Administration Adverse Events Reporting System (FAERS) from the third quarter of 2014 and ending in the third quarter of 2017. We then used the GeneCards database to map the pharmacogenomic biomarkers associated with the most reported FAERS drugs. Data homogenization and statistics analysis were all conducted in R for statistical programming.
We identified risperidone (10.64%) as the compound with the most reported ADRs from all reported cases. Males represented 90.1% of reported risperidone cases with gynecomastia being the most reported ADR. Ibuprofen OR=188 (95% CI, 105.00 - 335.00) and quetiapine fumarate OR=116 (95% CI, 48.40 - 278.00) were associated with the highest odds of completed suicide in teenagers. Ondansetron hydrochloride OR=7.12 (95% CI, 1.59 - 31.9) resulted in the highest odds of pneumothorax. Lastly, olanzapine (8.96%) represented the compound with the most reported drug-drug interactions cases, while valproic acid OR=221 (95% CI, 93.900 - 522.00) was associated with the highest odds of drug-drug interactions.
Despite any data limitations, physicians prescribing risperidone in males should be aware of the high rates of adverse drug events and an alternative psychotropic should be considered in male patients. Further, patients with a history of pneumothorax or genetically predisposed to pneumothorax should be considered for an alternative antiemetic to ondansetron hydrochloride, due to increased odds associated with the drug and adverse event.</description><identifier>ISSN: 2046-1402</identifier><identifier>EISSN: 2046-1402</identifier><identifier>DOI: 10.12688/f1000research.14970.2</identifier><identifier>PMID: 30271581</identifier><language>eng</language><publisher>England: Faculty of 1000 Ltd</publisher><subject>Adolescent ; Adverse Drug Reaction Reporting Systems ; Biomarkers ; Child ; Collaboration ; Copyright ; Data processing ; Databases, Factual ; Drug dosages ; Drug stores ; Drug-Related Side Effects and Adverse Reactions - complications ; Education ; Female ; Genomics ; Gynecomastia ; Gynecomastia - etiology ; Health care ; Hospitals ; Humans ; Ibuprofen ; Male ; Morbidity ; Olanzapine ; Patient safety ; Pharmacists ; Pharmacogenomics ; Pharmacology ; Pharmacology, Clinical - methods ; Pharmacovigilance ; Physicians ; Pneumothorax ; Pneumothorax - etiology ; Precision medicine ; Prescription drugs ; Quetiapine ; Quetiapine fumarate ; Retrospective Studies ; Risperidone ; Risperidone - adverse effects ; Statistical analysis ; Suicide ; Training ; Treatment Outcome ; United States ; United States Food and Drug Administration ; Valproic acid</subject><ispartof>F1000 research, 2018, Vol.7, p.677-677</ispartof><rights>Copyright: © 2018 Eugene AR and Eugene B. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2018 Eugene AR and Eugene B 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5462-2394eb6d5e5586ada6f2c7a0de4b751d7ba3ae77e7f18b3cd5dfe662b0295e5e3</citedby><cites>FETCH-LOGICAL-c5462-2394eb6d5e5586ada6f2c7a0de4b751d7ba3ae77e7f18b3cd5dfe662b0295e5e3</cites><orcidid>0000-0002-2512-5454</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2114633711/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2114633711?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4022,25752,27922,27923,27924,37011,37012,44589,53790,53792,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30271581$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eugene, Andy R</creatorcontrib><creatorcontrib>Eugene, Beata</creatorcontrib><title>An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers</title><title>F1000 research</title><addtitle>F1000Res</addtitle><description>Adverse drug reactions (ADRs) are a major cause of hospital admissions, prolonged hospital stays, morbidity, and drug-related mortality. In this study, we sought to identify the most frequently reported medications and associated side effects in adolescent-aged patients in an effort to prioritize clinical pharmacology consultation efforts for hospitals seeking to improve patient safety.
Quarterly reported data were obtained from the United States Food and Drug Administration Adverse Events Reporting System (FAERS) from the third quarter of 2014 and ending in the third quarter of 2017. We then used the GeneCards database to map the pharmacogenomic biomarkers associated with the most reported FAERS drugs. Data homogenization and statistics analysis were all conducted in R for statistical programming.
We identified risperidone (10.64%) as the compound with the most reported ADRs from all reported cases. Males represented 90.1% of reported risperidone cases with gynecomastia being the most reported ADR. Ibuprofen OR=188 (95% CI, 105.00 - 335.00) and quetiapine fumarate OR=116 (95% CI, 48.40 - 278.00) were associated with the highest odds of completed suicide in teenagers. Ondansetron hydrochloride OR=7.12 (95% CI, 1.59 - 31.9) resulted in the highest odds of pneumothorax. Lastly, olanzapine (8.96%) represented the compound with the most reported drug-drug interactions cases, while valproic acid OR=221 (95% CI, 93.900 - 522.00) was associated with the highest odds of drug-drug interactions.
Despite any data limitations, physicians prescribing risperidone in males should be aware of the high rates of adverse drug events and an alternative psychotropic should be considered in male patients. Further, patients with a history of pneumothorax or genetically predisposed to pneumothorax should be considered for an alternative antiemetic to ondansetron hydrochloride, due to increased odds associated with the drug and adverse event.</description><subject>Adolescent</subject><subject>Adverse Drug Reaction Reporting Systems</subject><subject>Biomarkers</subject><subject>Child</subject><subject>Collaboration</subject><subject>Copyright</subject><subject>Data processing</subject><subject>Databases, Factual</subject><subject>Drug dosages</subject><subject>Drug stores</subject><subject>Drug-Related Side Effects and Adverse Reactions - complications</subject><subject>Education</subject><subject>Female</subject><subject>Genomics</subject><subject>Gynecomastia</subject><subject>Gynecomastia - etiology</subject><subject>Health care</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Ibuprofen</subject><subject>Male</subject><subject>Morbidity</subject><subject>Olanzapine</subject><subject>Patient safety</subject><subject>Pharmacists</subject><subject>Pharmacogenomics</subject><subject>Pharmacology</subject><subject>Pharmacology, Clinical - methods</subject><subject>Pharmacovigilance</subject><subject>Physicians</subject><subject>Pneumothorax</subject><subject>Pneumothorax - etiology</subject><subject>Precision medicine</subject><subject>Prescription drugs</subject><subject>Quetiapine</subject><subject>Quetiapine fumarate</subject><subject>Retrospective Studies</subject><subject>Risperidone</subject><subject>Risperidone - adverse effects</subject><subject>Statistical analysis</subject><subject>Suicide</subject><subject>Training</subject><subject>Treatment Outcome</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><subject>Valproic acid</subject><issn>2046-1402</issn><issn>2046-1402</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkt1q3DAQhU1paUKaVwiC3vRmt_qxJbsXhSX0JxDoTXstxtLYq8UruZK8sM_Sl63YTUO2VxKacz5mRqeq7hhdMy7b9uPAKKURE0I02zWrO0XX_FV1zWktV6ym_PWL-1V1m9KuGGjXCcnV2-pKUK5Y07Lr6s_GkzDPIebFu3wkQ4jETM47AxOZtxD3YMIUxiPJEZxHWx6PyRkHPpEciNvPMRyQzJAd-kxsXEaSYMB8_EQ2JGKOIc1osisi8DAVcyJhIGAPGBOeDRGhKEJBOk8yooexFN9VbwaYEt4-nTfVr69fft5_Xz3--PZwv3lcmaaWfMVFV2MvbYNN00qwIAduFFCLda8aZlUPAlApVANre2FsYweUkveUd8WD4qZ6OHNtgJ2eo9tDPOoATp8eQhw1xOzMhNrKThnRAvZ2qHswbS0FNJ3gtjFU2a6wPp9Z89Lv0ZqykwjTBfSy4t1Wj-GgJatFJ0QBfHgCxPB7wZT13iWD0wQew5I0Z6zhZSxKi_T9f9JdWGLZ8UlVOhOKsaKSZ5UpP5EiDs_NMKpPcdIXcdKnOGlejHcvR3m2_QuP-At-BM4N</recordid><startdate>2018</startdate><enddate>2018</enddate><creator>Eugene, Andy R</creator><creator>Eugene, Beata</creator><general>Faculty of 1000 Ltd</general><general>F1000 Research Limited</general><general>F1000 Research Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2512-5454</orcidid></search><sort><creationdate>2018</creationdate><title>An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers</title><author>Eugene, Andy R ; Eugene, Beata</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5462-2394eb6d5e5586ada6f2c7a0de4b751d7ba3ae77e7f18b3cd5dfe662b0295e5e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adolescent</topic><topic>Adverse Drug Reaction Reporting Systems</topic><topic>Biomarkers</topic><topic>Child</topic><topic>Collaboration</topic><topic>Copyright</topic><topic>Data processing</topic><topic>Databases, Factual</topic><topic>Drug dosages</topic><topic>Drug stores</topic><topic>Drug-Related Side Effects and Adverse Reactions - complications</topic><topic>Education</topic><topic>Female</topic><topic>Genomics</topic><topic>Gynecomastia</topic><topic>Gynecomastia - etiology</topic><topic>Health care</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Ibuprofen</topic><topic>Male</topic><topic>Morbidity</topic><topic>Olanzapine</topic><topic>Patient safety</topic><topic>Pharmacists</topic><topic>Pharmacogenomics</topic><topic>Pharmacology</topic><topic>Pharmacology, Clinical - methods</topic><topic>Pharmacovigilance</topic><topic>Physicians</topic><topic>Pneumothorax</topic><topic>Pneumothorax - etiology</topic><topic>Precision medicine</topic><topic>Prescription drugs</topic><topic>Quetiapine</topic><topic>Quetiapine fumarate</topic><topic>Retrospective Studies</topic><topic>Risperidone</topic><topic>Risperidone - adverse effects</topic><topic>Statistical analysis</topic><topic>Suicide</topic><topic>Training</topic><topic>Treatment Outcome</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><topic>Valproic acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eugene, Andy R</creatorcontrib><creatorcontrib>Eugene, Beata</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>F1000 research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eugene, Andy R</au><au>Eugene, Beata</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers</atitle><jtitle>F1000 research</jtitle><addtitle>F1000Res</addtitle><date>2018</date><risdate>2018</risdate><volume>7</volume><spage>677</spage><epage>677</epage><pages>677-677</pages><issn>2046-1402</issn><eissn>2046-1402</eissn><abstract>Adverse drug reactions (ADRs) are a major cause of hospital admissions, prolonged hospital stays, morbidity, and drug-related mortality. In this study, we sought to identify the most frequently reported medications and associated side effects in adolescent-aged patients in an effort to prioritize clinical pharmacology consultation efforts for hospitals seeking to improve patient safety.
Quarterly reported data were obtained from the United States Food and Drug Administration Adverse Events Reporting System (FAERS) from the third quarter of 2014 and ending in the third quarter of 2017. We then used the GeneCards database to map the pharmacogenomic biomarkers associated with the most reported FAERS drugs. Data homogenization and statistics analysis were all conducted in R for statistical programming.
We identified risperidone (10.64%) as the compound with the most reported ADRs from all reported cases. Males represented 90.1% of reported risperidone cases with gynecomastia being the most reported ADR. Ibuprofen OR=188 (95% CI, 105.00 - 335.00) and quetiapine fumarate OR=116 (95% CI, 48.40 - 278.00) were associated with the highest odds of completed suicide in teenagers. Ondansetron hydrochloride OR=7.12 (95% CI, 1.59 - 31.9) resulted in the highest odds of pneumothorax. Lastly, olanzapine (8.96%) represented the compound with the most reported drug-drug interactions cases, while valproic acid OR=221 (95% CI, 93.900 - 522.00) was associated with the highest odds of drug-drug interactions.
Despite any data limitations, physicians prescribing risperidone in males should be aware of the high rates of adverse drug events and an alternative psychotropic should be considered in male patients. Further, patients with a history of pneumothorax or genetically predisposed to pneumothorax should be considered for an alternative antiemetic to ondansetron hydrochloride, due to increased odds associated with the drug and adverse event.</abstract><cop>England</cop><pub>Faculty of 1000 Ltd</pub><pmid>30271581</pmid><doi>10.12688/f1000research.14970.2</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-2512-5454</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2046-1402 |
ispartof | F1000 research, 2018, Vol.7, p.677-677 |
issn | 2046-1402 2046-1402 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_d697c38aebdf4bac8463a5932d5c07d9 |
source | Publicly Available Content Database; PubMed Central |
subjects | Adolescent Adverse Drug Reaction Reporting Systems Biomarkers Child Collaboration Copyright Data processing Databases, Factual Drug dosages Drug stores Drug-Related Side Effects and Adverse Reactions - complications Education Female Genomics Gynecomastia Gynecomastia - etiology Health care Hospitals Humans Ibuprofen Male Morbidity Olanzapine Patient safety Pharmacists Pharmacogenomics Pharmacology Pharmacology, Clinical - methods Pharmacovigilance Physicians Pneumothorax Pneumothorax - etiology Precision medicine Prescription drugs Quetiapine Quetiapine fumarate Retrospective Studies Risperidone Risperidone - adverse effects Statistical analysis Suicide Training Treatment Outcome United States United States Food and Drug Administration Valproic acid |
title | An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T15%3A34%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20opportunity%20for%20clinical%20pharmacology%20trained%20physicians%20to%20improve%20patient%20drug%20safety:%20A%20retrospective%20analysis%20of%20adverse%20drug%20reactions%20in%20teenagers&rft.jtitle=F1000%20research&rft.au=Eugene,%20Andy%20R&rft.date=2018&rft.volume=7&rft.spage=677&rft.epage=677&rft.pages=677-677&rft.issn=2046-1402&rft.eissn=2046-1402&rft_id=info:doi/10.12688/f1000research.14970.2&rft_dat=%3Cproquest_doaj_%3E2115275100%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5462-2394eb6d5e5586ada6f2c7a0de4b751d7ba3ae77e7f18b3cd5dfe662b0295e5e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2114633711&rft_id=info:pmid/30271581&rfr_iscdi=true |